Everpure looks like a plain enterprise storage company, but its flash design and new AI-focused features could turn it into a key supplier for the biggest data-center buildout. The upside depends on landing more mega-scale customers and proving it can help companies run AI workloads faster and cheaper—while real competition and a few warning signs could get in the way.Read more

Pro Medicus’ hospital imaging software is becoming the tool radiologists insist on using, and a recent stumble has many investors treating it like the business is slowing for good. The real story is whether new big hospital wins, a move into heart imaging, and more overseas growth can keep momentum going—and what could derail it.Read more

Beam Therapeutics is betting that a newer, more precise form of gene editing can fix genetic diseases without the DNA damage risks tied to older approaches. Early human results in a liver-targeted program, plus a push to remove harsh chemotherapy from stem cell transplants, could open much larger patient groups—but competition and clinical execution still matter.Read more